229 related articles for article (PubMed ID: 22831177)
1. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
[TBL] [Abstract][Full Text] [Related]
2. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
3. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Lipton A; Goessl C
Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
[TBL] [Abstract][Full Text] [Related]
5. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
8. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibition in the treatment of bone metastases.
Lipton A; Jun S
Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
[TBL] [Abstract][Full Text] [Related]
10. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for treatment of breast cancer bone metastases and beyond.
Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
[TBL] [Abstract][Full Text] [Related]
12. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K; Ito K
Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; MartÃn M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
15. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
Takahashi S
Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
[TBL] [Abstract][Full Text] [Related]
16. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
Perez Ruixo JJ; Doshi S; Sohn W; Chow A
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
18. Denosumab for the treatment of osteoporosis and cancer-related conditions.
Lewiecki EM; Bilezikian JP
Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
[TBL] [Abstract][Full Text] [Related]
19. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
20. [Cancer treatment-induced bone loss. Treatment for breast cancer].
Yamada K; Kohno N
Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]